Table 7.

TRIAL II. Dynamics of overall monthly changes in total values from individual symptoms determined according to Kupperman’s Menopausal Index (KMI) and Greene’s Menopausal Score (GMS) recorded between Admission point (A), at four monthly sampling points (Month Model)^a and Placebo (P) versus Maca-GO (M) contrast (Treatment Model) according to four intermittent sequence of Placebo application during four month study as per Trial II & III (n=42)

Treatment	Admission A	After Month 1 P	After Month 2 P	After Month 3 M	After Month 4 M	SEDb	Placebo	Maca	SED	Pc
Kupperman’s Menopausal Index (KMI)
OPMMP	21.56	14.44	8.44	7.67	16.33	1.62	15.39	8.06	1.38	<0.001
OPPMM	30.40	15.20	24.00	10.80	6.99	1.69	19.60	9.65	1.31	<0.001
OMMPP	29.64	13.09	9.45	14.88	19.58	1.52	17.21	11.27	1.30	<0.001
OMMPM	25.27	14.59	9.64	17.77	11.32	1.47	17.77	11.85	1.25	<0.001
SED		3.52	3.52	3.53	3.59		3.47	3.47
Greene’s Menopausal Score (GMS)
OPMMP	25.00	19.11	12.67	10.00	8.00	1.64	13.56	11.33	1.52	ns
OPPMM	25.80	10.90	8.60	8.90	3.30	1.55	9.75	6.10	1.44	<0.01
OMMPP	30.91	12.45	10.91	13.00	7.18	1.48	10.09	11.68	1.37	ns
OMMPM	26.91	18.64	15.91	16.36	12.73	1.48	16.36	15.76	1.58	ns
SED		4.28	4.28	4.28	4.28		4.35	4.04

^aFor explanation see Table 1;

^bSED, Standard error of differences;

^cP, Probabilities of significance. ns, not significant at P>0.05; P<0.05, significance at 5% probability level; P<0.01, significance at 1% probability level; P<0.001, significance at 0.1% probability.